Evidence map›Paper›PMID 42368216›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2026

Impella™-protected PCI in a post-CABG patient with advanced biventricular dysfunction and mitral regurgitation.

Mohamed Ayoub, Saad Ezad, Roberto Lorusso, Pieter Vriesendorp, Christophe Vandenbriele, Vasileios Panoulas

Abstract read
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed AyoubClinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany.
Saad EzadBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.
Roberto LorussoCardio-Thoracic Surgery Department, Maastricht University Medical Centre+, 6620 ER Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-1777-2045
Pieter VriesendorpCardiovascular Research Institute Maastricht (CARIM), 6229 ER Maastricht, The Netherlands.
Christophe VandenbrieleHeart Center AZORG, Campus Moorselbaan, Moorselbaan 164, 9300 Aalst, Belgium.ORCID https://orcid.org/0000-0003-2338-8346
Vasileios PanoulasHarefield Hospital, Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, Hill End Road, UB9 6JH, Harefield, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with advanced coronary artery disease (CAD), severely reduced left ventricular (LV) ejection fraction, and prior coronary artery bypass grafting (CABG) present with complex revascularization challenges requiring individualized, multidisciplinary decision-making and pre-procedural strategy planning. Protected percutaneous coronary intervention (PCI) using percutaneous temporary mechanical circulatory support, such as the Impella™ microaxial flow pump, may enable complex revascularization in carefully selected patients at high risk of peri-procedural haemodynamic compromise. We describe a male patient with advanced ischaemic cardiomyopathy, severe functional mitral regurgitation, and complex multivessel CAD, including chronic total occlusion (CTO) of the left anterior descending artery, following prior CABG. After Heart Team discussion and in the context of prohibitive surgical risk, a staged strategy was carefully planned pre-procedurally and then pursued with mitral transcatheter edge-to-edge repair, followed by prophylactic Impella-assisted PCI. Under haemodynamic support, retrograde CTO PCI via a patent saphenous vein graft was performed with drug-eluting stent implantation and intravascular ultrasound-confirmed optimization, achieving TIMI 3 flow. The patient remained haemodynamically stable, with an uneventful post-procedural course and no vascular or cardiac complications. This case illustrates how a staged Impella-protected PCI strategy can facilitate revascularization in post-CABG patients with advanced LV dysfunction and be integrated into a timely, planned, and patient-tailored approach accounting for ventricular function, valvular disease, and complex coronary anatomy when surgery is not feasible.

Indexed as

Chronic total occlusionHigh-risk PCIImpellaIschaemic cardiomyopathyMitral regurgitationMultivessel CADProtected PCIReduced LVEF

Identifiers

PMID42368216
PMCPMC13294563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.